Results 131 to 135 of about 8,394 (135)

Pharmacokinetics of CYP2C19- and CYP3A4-Metabolized Drugs in Cirrhosis Using a Whole-Body PBPK Approach. [PDF]

Pharmaceutics
Mu R, Gao J, Wang X, Ling J, Hu N, Yang H.   +5 more
europepmc   +1 more source

Genome edited intestine liver on a chip system for integrated intestinal hepatic drug absorption and metabolism evaluation. [PDF]

Sci Rep
Negoro R, Deguchi S, Yamazaki D, Takayama K, Fujita T.   +4 more
europepmc   +1 more source

Identification and validation of Novel Estrogen Biosynthesis Biomarkers in Sinonasal Inverted Papilloma. [PDF]

Int J Med Sci
Yang YF, Yu SH, Liao JB, Lin YH.
europepmc   +1 more source

Physiologically-Based Pharmacokinetic Modeling of the PARP Inhibitor Niraparib. [PDF]

CPT Pharmacometrics Syst Pharmacol
Lewis GJ, Jewell RC, Krishnatry AS, Taskar KS.   +3 more
europepmc   +1 more source

Fluvoxamine but not citalopram increases serum melatonin in healthy subjects - an indication that cytochrome P 450 CYP1A2 and CYP2C19 hydroxylate melatonin

European Journal of Clinical Pharmacology, 2000
The nocturnal serum melatonin (MT) level increases after ingestion of fluvoxamine (FLU)-- a selective serotonin re-uptake inhibitor (SSRI) with antidepressive properties. The mechanism behind the MT increase is unknown. Citalopram (CIT) is another SSRI. It is not known whether CIT affects the serum MT level.
C, von Bahr, C, Ursing, N, Yasui, G, Tybring, L, Bertilsson, S, Röjdmark   +5 more
openaire   +3 more sources